OptimizeRx Survey Shows Providers Believe They Have a Role in Discussing Care Costs with Patients
11 Februar 2019 - 2:31PM
OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital
health messaging for the pharmaceutical industry, announced today
its initial findings from a physician survey focused on
prescription drug costs. The Drug Cost Survey yields insights into
physician perspectives on the affordability of prescription drugs
and patient adherence to prescription regimens.
“The vast majority of Americans cited the costs of prescription
drugs as one of their top two health reform priorities in
2018,” said Miriam Paramore, president of OptimizeRx. “Further, it
is widely studied that affordability is a primary factor
contributing to medication non-adherence. We wanted to go directly
to physicians and gauge their opinions on the matter: How do they
view their role in discussing healthcare costs? Do patients
routinely ask about costs? These questions and more were included
in our survey.”
Initial findings from the OptimizeMDs Drug Cost Survey showed
that:
- Nearly all physicians believe they have a role to play in
discussing the cost of health care with patients (91 percent) and
are comfortable doing so (86 percent).
- Patients raise the issue of prescription drug costs with their
doctors nearly 40 percent of the time.
- Prescription drug costs are “very important” or “extremely
important” to the vast majority of doctors (73 percent) and impact
their prescribing decisions.
Patients and providers want to discuss the cost of
prescriptions, and providers help patients look for savings
opportunities through co-pay coupons and other patient assistance
programs. However, both parties are ham-strung by the lack of
information showing total drug price – including the true patient
out-of-pocket
price. Supplemented
by other industry findings, the results from OptimizeRx’s survey
illustrate the gap in communications among the stakeholders
involved in or affected by drug pricing: the party who make
the drugs and set the initial price (pharmaceutical manufacturers),
the party who sets the price for a benefit plan (payers), the party
who prescribes the drugs and need to know the price (providers) and
those have to take/adhere the drugs and pay its price
(patients).
Continued Paramore: “At OptimizeRx, we are committed to fill the
communications gap between patients, providers and the
pharmaceutical industry. By going to the physicians directly
through this first survey, we learned a lot about how we, as an
industry, can better communicate to address drug affordability and
adherence.”
Additional results from this survey will be released throughout
the coming months. OptimizeRx plans to facilitate a corollary
consumer survey to gauge their perspectives on financial
discussions, prescription affordability and medication
adherence.
Conducted between January 9 and 14, 2019, the survey included
responses from 642 physicians across a variety of specialties,
practice and/or hospital sizes and locations across the United
States. It was the first to be executed through OptimizeMDs, a
multi-specialty physician panel created by OptimizeRx to improve
the effectiveness of digital communication between pharma/life
sciences and physicians at the point-of-care. OptimizeMDs is
one of the brand support services available to pharmaceutical
manufacturers.
For more information on OptimizeRx or its OptimizeMDs physician
panel, visit www.optimizerx.com. To download the initial two-page
summary, visit info.optimizerx.com/survey-intro.
About OptimizeRx OptimizeRx®
(NASDAQ: OPRX) is one of the nation’s leading providers of digital
health messaging via electronic health records (EHRs), providing a
direct channel for pharma companies to communicate with healthcare
providers. The company’s cloud-based solution supports patient
adherence to medications by providing real-time access to financial
assistance, prior authorization, education, and critical clinical
information. The company’s network is comprised of leading EHR
platforms like Allscripts, Amazing Charts and Quest, and provides
more than half of the ambulatory patient market with access to
these benefits within their workflow at the point-of-care. For more
information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
Statements Certain information contained in this press
release includes “forward-looking statements” within the meaning of
The Private Securities Litigation Reform Act of 1995, including
statements related to the proposed public offering, the filing of
the registration statement and potential market opportunity for our
product candidates. We may, in some cases use terms such as
“predicts,” “believes,” “potential,” “continue,” “anticipates,”
“estimates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
the future events or outcomes to identify these forward-looking
statements. Our forward-looking statements are based on current
expectations that involve risks, potential changes in
circumstances, assumptions and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong, or be affected
by inaccurate assumptions we might make or by known or unknown
risks and uncertainties as a result of various important factors,
including the uncertainties related to market conditions, our
ability to satisfy the closing conditions of the offering, the
timing or occurrence of the closing, and the anticipated use of the
proceeds of the offering, which could change as a result of market
conditions or for other reasons. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to our business in general, please refer to our
prospectus supplement filed with the Securities and Exchange
Commission (SEC) on December 17, 2018 under the heading “Risk
Factors” and those documents incorporated by reference therein,
which includes our Annual Report on Form 10-K filed with the SEC on
March 8, 2018. You are cautioned not to place undue reliance on
these forward-looking statements, which are made only as of the
date of this press release. We undertake no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
OptimizeRx ContactDoug Baker, CFOTel (248)
651-6568 x807dbaker@optimizerx.com
Media Relations ContactNicole Brooks, Innsena
CommunicationsTel (860) 800-2344nicolebrooks@innsena.com
Investor Relations ContactRon Both, CMATel
(949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024